The Experts below are selected from a list of 127443 Experts worldwide ranked by ideXlab platform
Zhina Mei - One of the best experts on this subject based on the ideXlab platform.
-
antidiabetic effect of tibetan medicine tang kang fu san in db db mice via activation of pi3k akt and ampk pathways
Frontiers in Pharmacology, 2017Co-Authors: Ailu Dua, Zhongqiu Zhao, Weifang Liao, Sisi Liu, Tiexiang Gao, Hui Xiong, Zhina MeiAbstract:This study was to investigate the anti-diabetic effect and molecular mechanisms of Tang-Kang-Fu-San (TKFS), a traditional Tibetan medicine, in treating Type 2 diabetes mellitus of spontaneous diabetic db/db mice. Firstly HPLC fingerprint analysis was performed to gain the features of the chemical compositions of TKFS. Next different doses of TKFS (0.5 g/kg, 1.0 g/kg and 2.0 g/kg) were administrated via oral gavage to db/db mice and their controls for 4 weeks. TKFS significantly lowered hyperglycemia and ameliorated insulin resistance in db/db mice, indicated by results from multiple Tests, including fasting blood Glucose Test, intraperitoneal insulin and Glucose tolerance Tests, fasting serum insulin levels and homeostasis model assessment of insulin resistance analysis as well as histology of pancreas islets. TKFS also decreased concentrations of serum triglyceride, total and low-density lipoprotein cholesterol, even though it did not change the mouse body weights. Results from western blot and immunohistochemistry analysis indicated that TKFS reversed the down-regulation of p-Akt and p-AMPK, and increased the translocation of Glucose transporter type 4 in skeletal muscles of db/db mice. In all, TKFS had promising benefits in maintaining the Glucose homeostasis and reducing insulin resistance. The underlying molecular mechanisms are related to promote Akt and AMPK activation and Glucose transporter type 4 translocation in skeletal muscles. Our work showed that multicomponent Tibetan medicine TKFS acted synergistically on multiple molecular targets and signaling pathways to treat type 2 diabetes mellitus.
-
Antidiabetic Effect of Tibetan Medicine Tang-Kang-Fu-San in db/db Mice via Activation of PI3K/Akt and AMPK Pathways
Frontiers Media S.A., 2017Co-Authors: Ailu Dua, Zhongqiu Zhao, Weifang Liao, Sisi Liu, Tiexiang Gao, Hui Xiong, Zhina MeiAbstract:This study was to investigate the anti-diabetic effects and molecular mechanisms of Tang-Kang-Fu-San (TKFS), a traditional Tibetan medicine, in treating type 2 diabetes mellitus of spontaneous diabetic db/db mice. Firstly HPLC fingerprint analysis was performed to gain the features of the chemical compositions of TKFS. Next different doses of TKFS (0.5 g/kg, 1.0 g/kg, and 2.0 g/kg) were administrated via oral gavage to db/db mice and their controls for 4 weeks. TKFS significantly lowered hyperglycemia and ameliorated insulin resistance (IR) in db/db mice, indicated by results from multiple Tests, including fasting blood Glucose Test, intraperitoneal insulin and Glucose tolerance Tests, fasting serum insulin levels and homeostasis model assessment of IR analysis as well as histology of pancreas islets. TKFS also decreased concentrations of serum triglyceride, total and low-density lipoprotein cholesterol, even though it did not change the mouse body weights. Results from western blot and immunohistochemistry analysis indicated that TKFS reversed the down-regulation of p-Akt and p-AMPK, and increased the translocation of Glucose transporter type 4 in skeletal muscles of db/db mice. In all, TKFS had promising benefits in maintaining the Glucose homeostasis and reducing IR. The underlying molecular mechanisms are related to promote Akt and AMPK activation and Glucose transporter type 4 translocation in skeletal muscles. Our work showed that multicomponent Tibetan medicine TKFS acted synergistically on multiple molecular targets and signaling pathways to treat type 2 diabetes mellitus
Francoisrene Bertin - One of the best experts on this subject based on the ideXlab platform.
-
immunoreactive insulin stability in horses at risk of insulin dysregulation
Journal of Veterinary Internal Medicine, 2019Co-Authors: Dakota H Z Leschke, Genevieve S Muir, Jack K Hodgson, Mitchell Coyle, Remona Horn, Francoisrene BertinAbstract:BACKGROUND: Diseases associated with insulin dysregulation (ID), such as equine metabolic syndrome and pituitary pars intermedia dysfunction, are of interest to practitioners because of their association with laminitis. Accurate insulin concentration assessment is critical in diagnosing and managing these diseases. HYPOTHESIS/OBJECTIVES: To determine the effect of time, temperature, and collection tube type on insulin concentrations in horses at risk of ID. ANIMALS: Eight adult horses with body condition score >6/9. METHODS: In this prospective study, subjects underwent an infeed oral Glucose Test 2 hours before blood collection. Blood samples were divided into ethylenediaminetetraacetic acid, heparinized, or serum tubes and stored at 4 or 20°C. Tubes were centrifuged and analyzed for insulin by a chemiluminescent assay over 8 days. Changes in insulin concentrations were compared with a linear mixed effects model. RESULTS: An overall effect of time, tube type and temperature was identified (P = .01, P = 0.001, and P = 0.001, respectively). Serum and heparinized samples had similar concentrations for 3 days at 20°C and 8 days at 4°C; however, after 3 days at 20°C, heparinized samples had significantly higher insulin concentrations (P = .004, P = .03, and P = .03 on consecutive days). Ethylenediaminetetraacetic acid samples had significantly lower insulin concentrations regardless of time and temperature (P = .001 for all comparisons). CONCLUSIONS AND CLINICAL IMPORTANCE: These results suggest an ideal protocol to determine insulin concentrations involves using serum or heparinized samples with analysis occurring within 3 days at 20°C or 8 days at 4°C.
-
factors associated with survival laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction
Equine Veterinary Journal, 2019Co-Authors: Rainer Horn, C J Secombe, Allison J Stewart, N J Bamford, T Afonso, M Sutherland, J Buckerfield, Francoisrene BertinAbstract:Pituitary pars intermedia dysfunction (PPID) is a commonly described endocrine disorder in higher latitudes of the Northern hemisphere but the description of the disease at lower latitudes and in the Southern hemisphere is limited. Document the clinical features of PPID at different Australian latitudes and climates, and investigate factors associated with survival, laminitis and insulin dysregulation (ID). Retrospective study of 274 equids from eight institutions across Australia. A diagnosis of PPID was based on endogenous ACTH, overnight dexamethasone suppression Test, thyrotropin-releasing hormone stimulation Test or necropsy. Clinical and clinicopathologic characteristics of PPID and therapeutic responses were investigated. Laminitis was diagnosed by radiographic or histologic changes and ID was diagnosed based on endogenous insulin, an oral Glucose Test or a 2-step insulin-response Test. Being a pony, having a higher body condition score and pergolide administration were associated with survival. The clinical presentation of PPID changed with latitude and climate, with anhidrosis and polyuria/polydipsia more commonly recognised at lower latitudes. Laminitis was diagnosed in 89.9% of cases and ID was present in 76.5% of cases in which they were investigated. Despite the sample size, the lack of uniform Testing at all locations (primary or referral cases) and the incompleteness of data sets limited the power of the statistical analyses. PPID can present with variable signs at different latitudes and climates, and ID should be investigated in equids diagnosed with PPID. Adequate body condition and administration of pergolide are fundamental in PPID management.
Zhongqiu Zhao - One of the best experts on this subject based on the ideXlab platform.
-
antidiabetic effect of tibetan medicine tang kang fu san in db db mice via activation of pi3k akt and ampk pathways
Frontiers in Pharmacology, 2017Co-Authors: Ailu Dua, Zhongqiu Zhao, Weifang Liao, Sisi Liu, Tiexiang Gao, Hui Xiong, Zhina MeiAbstract:This study was to investigate the anti-diabetic effect and molecular mechanisms of Tang-Kang-Fu-San (TKFS), a traditional Tibetan medicine, in treating Type 2 diabetes mellitus of spontaneous diabetic db/db mice. Firstly HPLC fingerprint analysis was performed to gain the features of the chemical compositions of TKFS. Next different doses of TKFS (0.5 g/kg, 1.0 g/kg and 2.0 g/kg) were administrated via oral gavage to db/db mice and their controls for 4 weeks. TKFS significantly lowered hyperglycemia and ameliorated insulin resistance in db/db mice, indicated by results from multiple Tests, including fasting blood Glucose Test, intraperitoneal insulin and Glucose tolerance Tests, fasting serum insulin levels and homeostasis model assessment of insulin resistance analysis as well as histology of pancreas islets. TKFS also decreased concentrations of serum triglyceride, total and low-density lipoprotein cholesterol, even though it did not change the mouse body weights. Results from western blot and immunohistochemistry analysis indicated that TKFS reversed the down-regulation of p-Akt and p-AMPK, and increased the translocation of Glucose transporter type 4 in skeletal muscles of db/db mice. In all, TKFS had promising benefits in maintaining the Glucose homeostasis and reducing insulin resistance. The underlying molecular mechanisms are related to promote Akt and AMPK activation and Glucose transporter type 4 translocation in skeletal muscles. Our work showed that multicomponent Tibetan medicine TKFS acted synergistically on multiple molecular targets and signaling pathways to treat type 2 diabetes mellitus.
-
Antidiabetic Effect of Tibetan Medicine Tang-Kang-Fu-San in db/db Mice via Activation of PI3K/Akt and AMPK Pathways
Frontiers Media S.A., 2017Co-Authors: Ailu Dua, Zhongqiu Zhao, Weifang Liao, Sisi Liu, Tiexiang Gao, Hui Xiong, Zhina MeiAbstract:This study was to investigate the anti-diabetic effects and molecular mechanisms of Tang-Kang-Fu-San (TKFS), a traditional Tibetan medicine, in treating type 2 diabetes mellitus of spontaneous diabetic db/db mice. Firstly HPLC fingerprint analysis was performed to gain the features of the chemical compositions of TKFS. Next different doses of TKFS (0.5 g/kg, 1.0 g/kg, and 2.0 g/kg) were administrated via oral gavage to db/db mice and their controls for 4 weeks. TKFS significantly lowered hyperglycemia and ameliorated insulin resistance (IR) in db/db mice, indicated by results from multiple Tests, including fasting blood Glucose Test, intraperitoneal insulin and Glucose tolerance Tests, fasting serum insulin levels and homeostasis model assessment of IR analysis as well as histology of pancreas islets. TKFS also decreased concentrations of serum triglyceride, total and low-density lipoprotein cholesterol, even though it did not change the mouse body weights. Results from western blot and immunohistochemistry analysis indicated that TKFS reversed the down-regulation of p-Akt and p-AMPK, and increased the translocation of Glucose transporter type 4 in skeletal muscles of db/db mice. In all, TKFS had promising benefits in maintaining the Glucose homeostasis and reducing IR. The underlying molecular mechanisms are related to promote Akt and AMPK activation and Glucose transporter type 4 translocation in skeletal muscles. Our work showed that multicomponent Tibetan medicine TKFS acted synergistically on multiple molecular targets and signaling pathways to treat type 2 diabetes mellitus
Ailu Dua - One of the best experts on this subject based on the ideXlab platform.
-
antidiabetic effect of tibetan medicine tang kang fu san in db db mice via activation of pi3k akt and ampk pathways
Frontiers in Pharmacology, 2017Co-Authors: Ailu Dua, Zhongqiu Zhao, Weifang Liao, Sisi Liu, Tiexiang Gao, Hui Xiong, Zhina MeiAbstract:This study was to investigate the anti-diabetic effect and molecular mechanisms of Tang-Kang-Fu-San (TKFS), a traditional Tibetan medicine, in treating Type 2 diabetes mellitus of spontaneous diabetic db/db mice. Firstly HPLC fingerprint analysis was performed to gain the features of the chemical compositions of TKFS. Next different doses of TKFS (0.5 g/kg, 1.0 g/kg and 2.0 g/kg) were administrated via oral gavage to db/db mice and their controls for 4 weeks. TKFS significantly lowered hyperglycemia and ameliorated insulin resistance in db/db mice, indicated by results from multiple Tests, including fasting blood Glucose Test, intraperitoneal insulin and Glucose tolerance Tests, fasting serum insulin levels and homeostasis model assessment of insulin resistance analysis as well as histology of pancreas islets. TKFS also decreased concentrations of serum triglyceride, total and low-density lipoprotein cholesterol, even though it did not change the mouse body weights. Results from western blot and immunohistochemistry analysis indicated that TKFS reversed the down-regulation of p-Akt and p-AMPK, and increased the translocation of Glucose transporter type 4 in skeletal muscles of db/db mice. In all, TKFS had promising benefits in maintaining the Glucose homeostasis and reducing insulin resistance. The underlying molecular mechanisms are related to promote Akt and AMPK activation and Glucose transporter type 4 translocation in skeletal muscles. Our work showed that multicomponent Tibetan medicine TKFS acted synergistically on multiple molecular targets and signaling pathways to treat type 2 diabetes mellitus.
-
Antidiabetic Effect of Tibetan Medicine Tang-Kang-Fu-San in db/db Mice via Activation of PI3K/Akt and AMPK Pathways
Frontiers Media S.A., 2017Co-Authors: Ailu Dua, Zhongqiu Zhao, Weifang Liao, Sisi Liu, Tiexiang Gao, Hui Xiong, Zhina MeiAbstract:This study was to investigate the anti-diabetic effects and molecular mechanisms of Tang-Kang-Fu-San (TKFS), a traditional Tibetan medicine, in treating type 2 diabetes mellitus of spontaneous diabetic db/db mice. Firstly HPLC fingerprint analysis was performed to gain the features of the chemical compositions of TKFS. Next different doses of TKFS (0.5 g/kg, 1.0 g/kg, and 2.0 g/kg) were administrated via oral gavage to db/db mice and their controls for 4 weeks. TKFS significantly lowered hyperglycemia and ameliorated insulin resistance (IR) in db/db mice, indicated by results from multiple Tests, including fasting blood Glucose Test, intraperitoneal insulin and Glucose tolerance Tests, fasting serum insulin levels and homeostasis model assessment of IR analysis as well as histology of pancreas islets. TKFS also decreased concentrations of serum triglyceride, total and low-density lipoprotein cholesterol, even though it did not change the mouse body weights. Results from western blot and immunohistochemistry analysis indicated that TKFS reversed the down-regulation of p-Akt and p-AMPK, and increased the translocation of Glucose transporter type 4 in skeletal muscles of db/db mice. In all, TKFS had promising benefits in maintaining the Glucose homeostasis and reducing IR. The underlying molecular mechanisms are related to promote Akt and AMPK activation and Glucose transporter type 4 translocation in skeletal muscles. Our work showed that multicomponent Tibetan medicine TKFS acted synergistically on multiple molecular targets and signaling pathways to treat type 2 diabetes mellitus
Michael D Crowell - One of the best experts on this subject based on the ideXlab platform.
-
the effects of tegaserod a 5 ht4 receptor agonist on gastric emptying in a murine model of diabetes mellitus
Neurogastroenterology and Motility, 2005Co-Authors: Carole Mathis, Michael D Crowell, V A Schettler, T Yunus, Brian E LacyAbstract:The C57BLKS/J db/db transgenic mouse is a model of diabetes mellitus that has been shown to have delayed gastric emptying. We assessed gastric emptying rates in C57BLKS/J mice, and determined the effects of tegaserod, a new selective 5-HT4 receptor partial agonist, on gastric emptying. Methods: Gastric emptying rates of a 20% Glucose Test meal were determined in 12–20-week-old female db/db mice and control littermates. The effects of tegaserod (0.1–2.0 mg kg−1, i.p.) on gastric transit were Tested in a second group of db/db mice. Pretreatment with GR11308, a specific 5-HT4antagonist, was used to confirm the mechanism of action of tegaserod on gastric emptying. Results: Gastric emptying of Glucose was significantly slower in db/db mice than in control littermates. Tegaserod (0.1 mg kg−1) significantly accelerated the gastric emptying rate of Glucose in db/db mice, reducing the fraction of the meal remaining in the stomach at 30 min by 80%. GR11308 blocked the gastrokinetic effects of tegaserod. Conclusions: Gastric emptying was impaired in db/db mice. Low dose tegaserod improved gastric emptying rates in this model of gastroparesis through the activation of 5-HT4 receptors. These findings suggest that 5-HT4 receptor agonists may prove useful for improving delayed gastric emptying in gastroparesis.